Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Synlait founder Penno to step down as CEO after 12 years

Synlait founder Penno to step down as CEO after 12 years, will remain a director

By Jonathan Underhill

Nov. 29 (BusinessDesk) - Synlait Milk founder and chief executive John Penno is to step down after 12 years leading the Dunsandel-based milk processor, whose shares have almost tripled since listing in July 2013.

Penno will step down in the next 12 months in what the company said would be an orderly transition. He will stay on during an international search for his successor.

Penno, who has spent a total of 17 years with the company, said he was " looking forward to getting back to my entrepreneurial roots and will be looking for opportunities to get involved with start-ups and young companies, which is where my wife, Maury, and I want to continue to make a contribution."

Synlait has grown from a start-up in the early 2000s to a company with a market value of $1.4 billion today and customers including high-flying milk marketer A2 Milk. It was initially rebuffed in its attempts to go public by local investors and instead turned to China's Bright Dairy for equity capital to fund its growth. Bright Dairy now owns 39 percent of the company.

In September Synlait posted an 11 percent gain in full-year profit and flagged further growth this year while signalling a move into branded consumer goods. Its shares touched a record high $8.25 on Oct. 30.

"From this platform, the company is looking for a CEO with the skills and experiences to take Synlait up another level," chair Graeme Milne said in a statement. "We have already signalled to shareholders our intention to continue to develop our infant formula business, and enter new categories where there are significant opportunities."

Discussing the move into new markets on a conference call in September, Penno said: "Up until now we've been strictly B2B, which has been very important during start-up." The company would move into branded products "where no conflict exists with existing partnerships" which meant it was "unlikely to be in infant formula", where companies such as A2 have very strong brands. "We do see areas in new categories that could be Synlait branded," he said.

In August Synlait announced plans to triple sales of infant formula to Sichuan-based New Hope Nutritionals, which is already its second-largest customer for finished infant formula and its largest under a Chinese label. Synlait took a 25 percent stake in New Hope in 2015.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Marine And Freshwater Reports: EDS Calls For Urgent Action On Marine Management

“There are some big issues to address. These include many marine species and habitats that are in serious trouble. Of the sample investigated, the report finds that 22% of marine mammals, 90% of seabirds and 80% of shorebirds are threatened with or actually at risk of extinction..." More>>

ALSO:

$7.5 Billion Surplus: Government Accounts "Show Strong Economy"

“The surplus and low levels of debt show the economy is in good shape. This allows the Government to spend more on infrastructure and make record investments in health and education,” Grant Robertson says. More>>

ALSO:

New OIO Application Trumps Judicial Review: OceanaGold Cleared To Buy Land For Waihi Tailings Expansion

In a surprise turnaround, the government has given OceanaGold a greenlight to buy land to expand its Waihi mine after the application was previously turned down by Land Information Minister Eugenie Sage. More>>

ALSO:

Christchurch Rebuild: Fletcher Sued For $7.5m Over Justice Precinct

Fletcher Building is being sued for $7.5 million by utilities contractor Electrix, one of the subcontractors on the Christchurch Justice and Emergency Services Precinct. More>>

Three New Drugs: PHARMAC Signs Bundle Deal For More Cancer Medicines

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More>>

ALSO: